002603 以岭药业
已收盘 12-16 15:00:00
资讯
新帖
简况
中药材产业兴农书写责任答卷 以岭药业获评“2025企业社会责任公益榜样”
证券之星 · 12-12
中药材产业兴农书写责任答卷 以岭药业获评“2025企业社会责任公益榜样”
以岭药业（002603）披露召开2025年第二次临时股东大会通知，12月08日股价下跌1.32%
证券之星 · 12-08
以岭药业（002603）披露召开2025年第二次临时股东大会通知，12月08日股价下跌1.32%
6个中成药跻身国家医保目录新增名单，康缘、以岭、三九、方盛各有产品入选
智通财经网 · 12-08
6个中成药跻身国家医保目录新增名单，康缘、以岭、三九、方盛各有产品入选
以岭药业：子公司独家产品芪防鼻通片首次纳入国家医保目录
证券日报 · 12-07
以岭药业：子公司独家产品芪防鼻通片首次纳入国家医保目录
以岭药业拟将化学制剂国际产业化项目节余募集资金1.61亿元永久补流
中金财经 · 12-06
以岭药业拟将化学制剂国际产业化项目节余募集资金1.61亿元永久补流
以岭药业拟修订《公司章程》 删除监事会并强化董事会职能
中金财经 · 12-06
以岭药业拟修订《公司章程》 删除监事会并强化董事会职能
以岭药业荣膺“阳光”年度杰出药物研发创新企业
证券之星 · 12-01
以岭药业荣膺“阳光”年度杰出药物研发创新企业
以岭药业（002603）披露全资子公司药品注册申请进展公告，11月27日股价下跌0.21%
证券之星 · 11-27
以岭药业（002603）披露全资子公司药品注册申请进展公告，11月27日股价下跌0.21%
11月25日以岭药业涨5.91%，长信金利趋势混合A基金重仓该股
证券之星 · 11-25
11月25日以岭药业涨5.91%，长信金利趋势混合A基金重仓该股
“冀”往开来铸春秋 | 以岭药业：以络病理论为根 铸中医药创新之魂
证券之星 · 11-25
“冀”往开来铸春秋 | 以岭药业：以络病理论为根 铸中医药创新之魂
“冀”往开来铸春秋 | 以岭药业：以络病理论为根 铸中医药创新之魂
证券之星 · 11-20
“冀”往开来铸春秋 | 以岭药业：以络病理论为根 铸中医药创新之魂
以岭药业（002603）披露收到化学原料药上市申请批准通知书，11月12日股价下跌2.25%
证券之星 · 11-12
以岭药业（002603）披露收到化学原料药上市申请批准通知书，11月12日股价下跌2.25%
以岭药业：公司产品尚未针对该病毒开展临床试验
证券之星 · 11-12
以岭药业：公司产品尚未针对该病毒开展临床试验
以岭药业：已获批上市药品不允许随意更改产品名称
证券之星 · 11-12
以岭药业：已获批上市药品不允许随意更改产品名称
以岭药业(002603.SZ)获得“盐酸美金刚”化学原料药上市申请批准
智通财经 · 11-12
以岭药业(002603.SZ)获得“盐酸美金刚”化学原料药上市申请批准
11月11日以岭药业涨6.61%，长信金利趋势混合A基金重仓该股
证券之星 · 11-11
11月11日以岭药业涨6.61%，长信金利趋势混合A基金重仓该股
以岭药业与乐药集团达成合作 共拓医药健康产业新篇章
证券之星 · 11-07
以岭药业与乐药集团达成合作 共拓医药健康产业新篇章
以岭药业(002603)：经营质量健康 业绩符合预期
证券之星 · 11-06
以岭药业(002603)：经营质量健康 业绩符合预期
以岭药业：全资孙公司阿那曲唑原料药获上市申请批准通知书
证券之星 · 10-30
以岭药业：全资孙公司阿那曲唑原料药获上市申请批准通知书
【国投证券 | 医药】以岭药业三季报点评：2025Q1-3利润端恢复性高增，创新管线筑牢长期护城河
证券之星 · 10-28
【国投证券 | 医药】以岭药业三季报点评：2025Q1-3利润端恢复性高增，创新管线筑牢长期护城河
加载更多
公司概况
公司名称：
石家庄以岭药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-07-28
主营业务：
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊和芪苈强心胶囊。公司先后多次承担国家及省部级科研计划项目，荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。
发行价格：
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":17.08,"timestamp":1765868616000,"preClose":17.56,"halted":0,"volume":17775000,"delay":0,"changeRate":-0.0273,"floatShares":1377000000,"shares":1671000000,"eps":-0.167,"marketStatus":"已收盘","change":-0.48,"latestTime":"12-16 15:00:00","open":17.52,"high":17.53,"low":17.08,"amount":306000000,"amplitude":0.0256,"askPrice":17.09,"askSize":154,"bidPrice":17.08,"bidSize":1121,"shortable":0,"etf":0,"ttmEps":-0.167,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"adjPreClose":17.56,"symbolType":"stock","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":19.32,"lowLimit":15.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.74,"roa":"--","roe":"9.34%","epsLYR":-0.4337,"committee":0.196492,"marketValue":28536000000,"turnoverRate":0.0129,"status":1,"floatMarketCap":23517000000},"requestUrl":"/m/hq/s/002603","defaultTab":"news","newsList":[{"id":"2590557595","title":"中药材产业兴农书写责任答卷 以岭药业获评“2025企业社会责任公益榜样”","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590557595?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:33","pubTimestamp":1765524796,"startTime":"0","endTime":"0","summary":"12月9日，2025(第九届)企业社会责任活动在深圳举行，现场发布了深蓝媒体智库企业社会责任优秀案例榜单。以岭药业凭借在乡村振兴与生态保护领域的突出实践，获评“2025年度企业社会责任公益榜样”。作为中医药行业标杆，以岭药业始终将社会责任融入发展战略，构建起特色ESG实践体系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025121200018577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0097","BK0239","BK0042","161912","BK0046"],"gpt_icon":0},{"id":"2589336793","title":"以岭药业（002603）披露召开2025年第二次临时股东大会通知，12月08日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589336793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589336793?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:43","pubTimestamp":1765186986,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，以岭药业报收于17.95元，较前一交易日下跌1.32%，最新总市值为299.89亿元。公司近日发布公告，宣布将于2025年12月22日召开2025年第二次临时股东大会，会议由董事会召集，采用现场表决与网络投票相结合的方式。其中，修改《公司章程》为特别决议事项，需经出席股东大会的股东所持表决权的2/3以上通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800021671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002603","BK0188","BK0042","BK0097","BK0239"],"gpt_icon":0},{"id":"2589803385","title":"6个中成药跻身国家医保目录新增名单，康缘、以岭、三九、方盛各有产品入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2589803385","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589803385?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:31","pubTimestamp":1765164685,"startTime":"0","endTime":"0","summary":"根据国家医保局披露的名单，此次新增的6个中成药品种分别为：温阳解毒颗粒、参郁宁神片、养血祛风止痛颗粒、益气清肺颗粒、玉女煎颗粒、芪防鼻通片，其中包括3个1.1类新药，3个3类新药。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"6个中成药跻身国家医保目录新增名单，康缘、以岭、三九、方盛各有产品入选","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0046","BK0060","BK0028","BK0097","BK0175","BK0010","002603","BK0188","600557","BK0183","603998","BK0012","BK0185","BK0042","BK0239","000999","BK0196"],"gpt_icon":0},{"id":"2589870690","title":"以岭药业：子公司独家产品芪防鼻通片首次纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589870690","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589870690?lang=zh_cn&edition=full","pubTime":"2025-12-07 20:36","pubTimestamp":1765110960,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月7日晚间，以岭药业发布公告称，公司全资子公司北京以岭药业有限公司独家产品芪防鼻通片通过了医保谈判，首次被纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyswc3253779.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyswc3253779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0046","BK0042","BK0097","002603","BK0239"],"gpt_icon":0},{"id":"2589633823","title":"以岭药业拟将化学制剂国际产业化项目节余募集资金1.61亿元永久补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2589633823","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589633823?lang=zh_cn&edition=full","pubTime":"2025-12-06 19:01","pubTimestamp":1765018872,"startTime":"0","endTime":"0","summary":"中访网数据 石家庄以岭药业股份有限公司于2025年12月5日召开董事会及监事会会议，审议通过了关于公司2017年非公开发行股票募集资金投资项目结项并将节余募集资金永久补充流动资金的议案。本次拟结项的项目为“化学制剂国际产业化项目”。截至2025年11月30日，该项目承诺投入募集资金总额为54,513.40万元，已累计投入38,411.41万元，节余募集资金16,101.99万元。公司计划将上述节余资金永久补充流动资金，用于日常生产经营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251206/31848935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002603","BK0042","BK0188","BK0046","BK0097","BK0239"],"gpt_icon":0},{"id":"2589840483","title":"以岭药业拟修订《公司章程》 删除监事会并强化董事会职能","url":"https://stock-news.laohu8.com/highlight/detail?id=2589840483","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589840483?lang=zh_cn&edition=full","pubTime":"2025-12-06 16:36","pubTimestamp":1765010162,"startTime":"0","endTime":"0","summary":"中访网数据 石家庄以岭药业股份有限公司于2025年12月5日召开董事会，审议通过了关于修改《公司章程》的议案。本次修订旨在适应新《公司法》等法规要求，并对公司治理结构进行重大调整。该议案尚需提交公司股东大会审议批准后方可生效。此次章程修订标志着以岭药业公司治理模式向董事会中心主义转型，旨在进一步优化决策与监督机制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251206/31848908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","002603","BK0097","BK0188","BK0046","BK0042"],"gpt_icon":0},{"id":"2588103317","title":"以岭药业荣膺“阳光”年度杰出药物研发创新企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588103317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588103317?lang=zh_cn&edition=full","pubTime":"2025-12-01 10:59","pubTimestamp":1764557941,"startTime":"0","endTime":"0","summary":"11月26日，2025年第九届21世纪大健康产业竞争力研究“阳光”案例榜单正式揭晓。以岭药业凭借其持续的创新研发实力和丰硕的科技成果荣膺创新研发卓越类“年度杰出药物研发创新企业”。作为积极响应国家大健康战略的践行者，以岭药业始终将研发创新置于企业发展的核心位置，长期保持高强度的研发投入。数据显示，2025年前三季度，以岭药业研发费用达5.44亿元，占营收比例达9.27%；2019至2024年间，累计研发投入已超50亿元，持续领跑行业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025120100006720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002603","BK0188","BK0042","BK0097","BK0239"],"gpt_icon":0},{"id":"2586223750","title":"以岭药业（002603）披露全资子公司药品注册申请进展公告，11月27日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586223750","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586223750?lang=zh_cn&edition=full","pubTime":"2025-11-27 22:02","pubTimestamp":1764252146,"startTime":"0","endTime":"0","summary":"截至2025年11月27日收盘，以岭药业报收于19.13元，较前一交易日下跌0.21%，最新总市值为319.61亿元。该股当日开盘19.25元，最高19.37元，最低18.97元，成交额达7.07亿元，换手率为2.68%。公司近日发布公告称，其全资子公司北京以岭药业有限公司收到国家药品监督管理局通知，同意撤回‘柴黄利胆胶囊’药品注册申请。2024年6月，该注册申请曾获国家药监局受理。本次撤回预计不会对公司当期及未来生产经营与业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700038001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0097","002603","BK0239","BK0042"],"gpt_icon":0},{"id":"2586447529","title":"11月25日以岭药业涨5.91%，长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586447529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586447529?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:36","pubTimestamp":1764056180,"startTime":"0","endTime":"0","summary":"证券之星消息，11月25日以岭药业涨5.91%，收盘报19.16元，换手率4.46%，成交量61.39万手，成交额11.58亿元。重仓以岭药业的公募基金请见下表：该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为20.57。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500017435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0097","002603","BK0239","BK0042"],"gpt_icon":0},{"id":"2586414519","title":"“冀”往开来铸春秋 | 以岭药业：以络病理论为根 铸中医药创新之魂","url":"https://stock-news.laohu8.com/highlight/detail?id=2586414519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586414519?lang=zh_cn&edition=full","pubTime":"2025-11-25 08:57","pubTimestamp":1764032276,"startTime":"0","endTime":"0","summary":"以岭药业董事、董事会秘书吴瑞表示。以岭药业首次系统构建了“络病理论”体系，出版了《络病学》《脉络论》《气络论》等著作，被誉为“中医络病研究史上的第四个里程碑”。截至目前，以岭药业成功研发17个专利中药，覆盖心脑血管、呼吸、糖尿病、肿瘤、神经、泌尿、妇科、抗衰老等八大疾病领域，其中11个品种进入国家医保目录、5个进入国家基药目录，成为中医药创新转化的典范。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025112500004704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0097","002603","BK0188","BK0046"],"gpt_icon":0},{"id":"2584218243","title":"“冀”往开来铸春秋 | 以岭药业：以络病理论为根 铸中医药创新之魂","url":"https://stock-news.laohu8.com/highlight/detail?id=2584218243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584218243?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:32","pubTimestamp":1763631137,"startTime":"0","endTime":"0","summary":"以岭药业董事、董事会秘书吴瑞表示。以岭药业首次系统构建了“络病理论”体系，出版了《络病学》《脉络论》《气络论》等著作，被誉为“中医络病研究史上的第四个里程碑”。截至目前，以岭药业成功研发17个专利中药，覆盖心脑血管、呼吸、糖尿病、肿瘤、神经、泌尿、妇科、抗衰老等八大疾病领域，其中11个品种进入国家医保目录、5个进入国家基药目录，成为中医药创新转化的典范。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025112000026115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0097","BK0188","BK0042","BK0239","002603"],"gpt_icon":0},{"id":"2582377802","title":"以岭药业（002603）披露收到化学原料药上市申请批准通知书，11月12日股价下跌2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377802?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:19","pubTimestamp":1762957166,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，以岭药业报收于20.01元，较前一交易日下跌2.25%，最新总市值为334.31亿元。该股当日开盘20.58元，最高20.6元，最低19.85元，成交额达13.45亿元，换手率为4.86%。公司近日发布公告称，其全资孙公司万洋衡水制药有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，其提交的“盐酸美金刚”化学原料药上市申请已获批准，符合药品注册有关要求，可在国内市场销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002603","BK0042","BK0097","BK0188","BK0239"],"gpt_icon":0},{"id":"2582326799","title":"以岭药业：公司产品尚未针对该病毒开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2582326799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582326799?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:54","pubTimestamp":1762937657,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业(002603)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：连花清瘟是否可缓解基孔肯雅热病情以岭药业回复：投资者您好，公司产品尚未针对该病毒开展临床试验。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200026293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0188","BK0046","002603","BK0097"],"gpt_icon":0},{"id":"2582261173","title":"以岭药业：已获批上市药品不允许随意更改产品名称","url":"https://stock-news.laohu8.com/highlight/detail?id=2582261173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582261173?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:45","pubTimestamp":1762937129,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业(002603)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：看贵公司八子补肾胶囊新闻这么好的产品用这个名太土了，改为八子抗衰老，这样大气意义重大，销量估计直线上升。以岭药业回复：投资者您好，非常感谢您的建议！根据药监法规等相关规定，已获批上市药品不允许随意更改产品名称。如有需求，需按照重大变更提出补充申请。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200026078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0046","002603","BK0042","BK0239"],"gpt_icon":0},{"id":"2582332303","title":"以岭药业(002603.SZ)获得“盐酸美金刚”化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2582332303","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582332303?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:22","pubTimestamp":1762935745,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司全资孙公司万洋衡水制药有限公司(以下简称“衡水万洋”)收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，由衡水万洋提交的“盐酸美金刚”化学原料药上市申请已获批准。盐酸美金刚(MemantineHydrochloride)是一种电压依赖性、中等程度亲和力的非竞争性NMDA受体拮抗剂，它可以阻断谷氨酸浓度病理性升高导致的神经元损伤，治疗中重度至重度阿尔茨海默型痴呆。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"以岭药业(002603.SZ)获得“盐酸美金刚”化学原料药上市申请批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0046","BK0239","002603","BK0042","BK0097"],"gpt_icon":0},{"id":"2582356017","title":"11月11日以岭药业涨6.61%，长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582356017","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582356017?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:27","pubTimestamp":1762849676,"startTime":"0","endTime":"0","summary":"证券之星消息，11月11日以岭药业涨6.61%创60日新高，收盘报20.47元，换手率6.41%，成交量88.21万手，成交额17.58亿元。重仓以岭药业的公募基金请见下表：该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为20.52。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100025495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0046","BK0042","BK0188","BK0097","BK0239"],"gpt_icon":0},{"id":"2581102389","title":"以岭药业与乐药集团达成合作 共拓医药健康产业新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2581102389","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581102389?lang=zh_cn&edition=full","pubTime":"2025-11-07 09:15","pubTimestamp":1762478130,"startTime":"0","endTime":"0","summary":"11月3日，以岭药业与乐药集团正式签署合作协议，双方将基于“优势互补、合作共赢、共同发展”的原则，建立长期、稳定、全面的合作关系，共同推动中国医药健康产业的高质量发展。2025年8月，以岭药业与京东健康签署深化合作协议，共同启动“升级抗衰中心数字营销方案”项目。双方与会人员合影此次以岭药业与乐药集团的战略携手，不仅是双方发展战略的重要一步，也将为行业合作树立新标杆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025110700006957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002603","BK0188","BK0097","BK0042","BK0046"],"gpt_icon":0},{"id":"2581030050","title":"以岭药业(002603)：经营质量健康 业绩符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581030050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581030050?lang=zh_cn&edition=full","pubTime":"2025-11-06 14:33","pubTimestamp":1762410820,"startTime":"0","endTime":"0","summary":"事件公司发布2025 年第三季度报告10月28日晚，公司发布2025年第三季度报告，前三季度实现营业收入、归母净利润和扣非后净利润分别为58.68 亿元、10.00 亿元和9.66 亿元， 分别同比增长-7.82% 、80. 33% 和90.53%，业绩符合我们此前预期。预计Q4 随着基数压力减弱、行业秩序持续恢复，有望实现持续修复。目前公司呼吸系统品类渠道库存已经逐步回归到常规水平，随着终端库存效期到期，叠加销售旺季来临，预计Q4 有望恢复增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025110600018117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0239","BK0188","BK0097","002603"],"gpt_icon":0},{"id":"2579115759","title":"以岭药业：全资孙公司阿那曲唑原料药获上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2579115759","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579115759?lang=zh_cn&edition=full","pubTime":"2025-10-30 09:41","pubTimestamp":1761788464,"startTime":"0","endTime":"0","summary":"10月29日，以岭药业(002603.SZ)公告称，公司全资孙公司万洋衡水制药有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，阿那曲唑化学原料药上市申请已获批准。阿那曲唑是一种广泛应用于治疗雌激素相关肿瘤的药物，尤其是在绝经后的激素受体阳性(HR+)女乳腺癌患者中。以岭药业全资孙公司北京以岭生物工程技术有限公司持有阿那曲唑片制剂批文，该产品为集采产品，预计今年可实现原料药制剂一体化生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025103000011622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","002603","BK0046","BK0239","BK0042"],"gpt_icon":0},{"id":"2578984493","title":"【国投证券 | 医药】以岭药业三季报点评：2025Q1-3利润端恢复性高增，创新管线筑牢长期护城河","url":"https://stock-news.laohu8.com/highlight/detail?id=2578984493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578984493?lang=zh_cn&edition=full","pubTime":"2025-10-28 15:04","pubTimestamp":1761635099,"startTime":"0","endTime":"0","summary":"来源：国投证券医药研究 作者：胡雨晴事件：公司发布2025年三季报。单季度来看，2025Q3公司实现营业收入18.27亿元，同比增长3.78%；实现归母净利润3.32亿元、扣非归母净利润3.25亿元，由于2024Q3基数较低均同比大幅增长。2025Q1-3期间费用率优化，盈利质量显著改善。在毛利率提升与期间费用率优化等因素的共同驱动下，公司前三季度净利率同比增长8.36pct至16.99%，盈利质量显著改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025102800021510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK1574","BK0188","BK1161","BK0046","BK0239","BK0042","BK0097","161027","BK1515","002603"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765882085030,"stockEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.1658},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.2627},{"period":"1year","weight":0.034},{"period":"ytd","weight":0.116}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.0307},{"period":"3month","weight":0.0016},{"period":"6month","weight":0.1414},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.154}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"152746人(较上一季度减少10.22%)","perCapita":"9013股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊和芪苈强心胶囊。公司先后多次承担国家及省部级科研计划项目，荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}